ASCO 2024: ONCOassist Garners Global Support
Study shows positive Oncologists feedback on use of NCCN templates globally
A recent article published in the Journal of Clinical Oncology and presented as an abstract at the ASCO conference in Chicago, titled “Impact of Digital Tools in Oncology: A Global Analysis of the Adoption of ONCOassist and NCCN Chemotherapy Order Templates (NCCN Templates) in Collaboration with OncoAlert” revealed that ONCOassist’s approach was well received by over 80% of the 2,556 healthcare professional respondents.
ONCOassist: A Growing Global App for Oncologists
ONCOassist is a rapidly expanding global application designed for oncologists, incorporating NCCN Templates. These templates are standardized chemotherapy order templates that provide evidence-based content to ensure optimal cancer treatment protocols. The NCCN Templates offer comprehensive recommendations that cover various cancer treatments, helping oncologists deliver consistent, high-quality care.
Study Insights: Demographic Nuances
The study, which surveyed 2,556 healthcare professionals from 122 countries, revealed some nuanced findings. While the overall acceptance rate of the NCCN Templates was high, there were variations across different economic and geographic demographics. For instance, countries with lower income and medium/low HDI levels reported higher utilization rates (86%) compared to high-income countries (72%). This suggests that the value of these digital tools transcends economic barriers, indicating their global applicability and trust among oncologists.
Resonating with Oncologists Worldwide
The positive reception of ONCOassist and the NCCN Templates, as presented at ASCO 2024, underscores the significant impact these digital tools have on oncology practices worldwide. Their ability to provide quick, up-to-date, and reliable information is transforming how oncologists approach cancer treatment, ultimately enhancing patient care.
Thoughts from solli
How can other Oncology focused apps learn from this, harness this feedback and engage more effectively with global oncologists?
For more detailed insights and data, read the full abstract presented at ASCO here and the published article in the Journal of Clinical Oncology here.
